Literature DB >> 3316566

Ethics of drug studies in infants: how many samples are required for accurate estimation of pharmacokinetic parameters in neonates?

D Long1, G Koren, A James.   

Abstract

Our study aimed to determine the least number of samples that are required to obtain accurate pharmacokinetic parameters in neonates. Patients treated with either netilmicin or ceftazidime had between five and eight samples drawn for drug concentration measurement after the first or the last dose of the drug. Pharmacokinetic parameters were calculated using all the available points as a reference and then recalculated with 2, 3, or 4 points. Systemic clearance and volume of distribution were significantly different from the reference value when 2 points were used for netilmicin after the first dose and ceftazidime after the last dose. Had parameters obtained from 2 points been used, mean dosage would have been underestimated by 15% for ceftazidime and 11% for netilmicin, and some patients would have received only 65% of the dose calculated from all available points. When 3 points were used, dosage would have been underestimated by a mean of only 1% for ceftazidime and 5% for netilmicin when compared with the dosage estimated from the reference parameters. We conclude that 3 concentration time points may be all that are required for estimation of pharmacokinetic parameters sufficiently accurate for practical purposes in neonates.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3316566     DOI: 10.1016/s0022-3476(87)80219-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  7 in total

1.  Ethical considerations in the conduct of clinical pharmacokinetic studies.

Authors:  C K Svensson
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

Review 2.  Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications.

Authors:  J T Gilman
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

3.  Assessment of bioelectrical impedance for individualizing gentamicin therapy in neonates.

Authors:  J S Sidhu; B G Charles; E J Triggs; D I Tudehope; P H Gray; P A Steer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations.

Authors:  R E Kauffman; G L Kearns
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

Review 5.  Paediatric labelling requirements. Implications for pharmacokinetic studies.

Authors:  J T Wilson; G L Kearns; D Murphy; S J Yaffe
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics in infants and children. A reappraisal.

Authors:  G L Kearns; M D Reed
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

Review 7.  Invasiveness of pharmacokinetic studies in children: a systematic review.

Authors:  Mohammed I Altamimi; Imti Choonara; Helen Sammons
Journal:  BMJ Open       Date:  2016-07-18       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.